Cordis to Unveil 12-Month SELUTION SLR DEB Trial Results
By Azmed Devices Editorial Team
Cordis will present late-breaking 12-month data from its SELUTION4ISR and SELUTION DeNovo clinical trials at the TCT annual scientific symposium. These results aim to evaluate the clinical value and safety of the SELUTION SLR DEB.
According to Cordis, the company will present late-breaking 12-month results for two major coronary trials during the upcoming Transcatheter Cardiovascular Therapeutics symposium in San Francisco. The findings from the SELUTION4ISR and SELUTION DeNovo trials are scheduled for presentation on October 26, 2025.
According to Cordis, the SELUTION DeNovo trial involved 3,323 patients and compared the SELUTION SLR DEB first strategy against systematic drug-eluting stent use for treating de novo coronary artery disease. Additionally, the SELUTION4ISR trial included 418 patients and compared the device against standard of care for treating in-stent restenosis.
According to Cordis, these clinical studies are intended to provide the medical community with evidence regarding the safety and utility of drug-eluting balloons within the coronary treatment algorithm. Following the presentations, the company plans to host two specialized symposia to discuss the trial results with the lead investigators.
Source
This article summarizes an official Cordis announcement. Read the original at https://cordis.com/emea/news/cordis-to-unveil-12-month-selution-slr-deb-trial-results. Product availability in Azerbaijan is subject to local registration; contact Azmed Devices for current status.
